|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1600 GBX | +0.95% |
|
-5.88% | -37.25% |
| 02:15pm | WINNERS & LOSERS: capAI gains exclusive licence for Ageotype platform | AN |
| 07-21 | WINNERS & LOSERS: Harvest Minerals surges on Brazil portfolio takeover | AN |
| Market Cap | 4.14M 5.53M 4.85M 4.5M 7.79M 534M 7.91M 53.63M 20.99M 261M 20.77M 20.33M 903M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 4.04M 5.4M 4.73M 4.4M 7.61M 521M 7.72M 52.36M 20.49M 255M 20.28M 19.85M 881M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | +0.95% | ||
| 1 week | -5.88% | ||
| Current month | -11.11% | ||
| 1 month | -16.45% | ||
| 3 months | -11.11% | ||
| 6 months | -41.82% | ||
| Current year | -37.25% |
| 1 week | 0.16 |  | 0.18 |
| 1 month | 0.16 | | 0.22 |
| Current year | 0.15 | | 0.4 |
| 1 year | 0.07 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
CHM | Chairman | 53 | 05/02/2020 |
Julian Gilbert
CHM | Chairman | 65 | 28/07/2022 |
| Director/Board Member | 61 | 02/12/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.95% | -5.88% | +82.86% | -39.05% | 5.53M | |
| +0.88% | -0.26% | +45.97% | +153.88% | 1,037B | |
| +0.08% | +2.07% | +50.89% | +49.14% | 615B | |
| +0.78% | +0.09% | +33.62% | +77.83% | 448B | |
| +4.69% | +4.49% | +32.61% | +26.69% | 326B | |
| +0.34% | +1.35% | +34.15% | +37.58% | 293B | |
| -1.16% | -0.57% | +17.63% | +16.47% | 264B | |
| -0.23% | -4.60% | -27.65% | -41.75% | 216B | |
| -0.45% | -2.18% | +17.55% | +54.40% | 198B | |
| -1.14% | -6.07% | +12.74% | +64.86% | 162B | |
| Average | +0.57% | +0.73% | +30.04% | +40.00% | 355.74B | |
| Weighted average by Cap. | +0.75% | +1.47% | +33.41% | +73.35% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.87M -4.27M -3.96M -6.86M -470M -6.96M -47.21M -18.48M -230M -18.29M -17.89M -795M | -653K -873K -765K -710K -1.23M -84.25M -1.25M -8.46M -3.31M -41.22M -3.28M -3.21M -142M |
| Net Debt | -20.21K -27.04K -23.69K -21.99K -38.08K -2.61M -38.64K -262K -103K -1.28M -101K -99.31K -4.41M | -97.55K -131K -114K -106K -184K -12.59M -187K -1.26M -495K -6.16M -490K -479K -21.29M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | GBX 0.1600 | +0.95% | 9,226,594 |
| 22/07/26 | GBX 0.1585 | -6.76% | 3,252,227 |
| 21/07/26 | GBX 0.1700 | +7.26% | 10,299,499 |
| 20/07/26 | GBX 0.1585 | -6.76% | 489,777 |
| 17/07/26 | GBX 0.1700 | 0.00% | 4,458,239 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
